Mallinckrodt Pharmaceuticals is dedicated to providing safe and effective medications and therapies for the treatment of patients as well as safety within the workplace, and the company is proud to serve as the exclusive sponsor for Patient Safety Awareness Week (PSAW), held March 12-18, 2017, by the National Patient Safety Foundation (NPSF).
Research suggests that as many as 440,000 patients die each year as a result of preventable medical harm, and that many others suffer significant and lasting morbidity, and quality-of-life implications. Given this evidence, NPSF advocates for addressing patient safety as a serious public health concern.
The week is a hallmark of NPSF’s “United for Patient Safety” campaign that highlights and reinforces how everyone within the health care system has a role to play in keeping patients safe and free from harm. This ongoing education and engagement campaign works to bring together diverse organizations with a commitment to patient safety and the general public to learn more about the topic, start important dialogue, and take action to improve safety conditions.
The National Patient Safety Foundation’s vision is to create a world where patients and those who care for them are free from harm. Since 1997, NPSF has partnered with patients and families, the health care community, and key stakeholders to advance patient safety and health care workforce safety and disseminate strategies to prevent harm. Learn more at www.NPSF.org.